On March 9, 2026, FDA issued a Federal Register Notice, announcing the availability of a draft guidance for industry entitled “Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection.” FDA believes the guidance will assist drug manufacturers who choose to respond to FDA following the issuance of an FDA Form 483 Inspectional Observations (FDA 483). FDA is soliciting comments on this draft guidance until May 8, 2026.
Background on Inspections and FDA 483s
Section 704 of the FDCA authorizes FDA to conduct inspections at reasonable times, within reasonable limits, and in a reasonable manner. FDA conducts pre-approval, pre-license, for-cause, or routine surveillance inspections at establishments manufacturing products regulated by FDA as drugs. Establishments manufacturing drugs are required to comply with applicable current good manufacturing practice (CGMP) requirements under the Federal Food, Drug, and Cosmetic Act (FDCA), specifically 501(a)(2)(B) of the FDCA (21 USC 351(a)(2)(B)), and 21 CFR part 210, 21 CFR part 211, 21 CFR part 212, 21 CFR part 4, 21 CFR part 226, and 21 CFR parts 600-680, as applicable..
If, during the course of the inspection, an FDA investigator identifies objectionable conditions or practices with respect to an FDA-regulated drug that, in the investigator’s judgment, may constitute a violation of the FDCA, FDA can issue an FDA 483. An FDA 483 contains inspectional observations made by an FDA representative during the inspection, but does not represent FDA’s final findings or conclusions about an establishment’s compliance with CGMP requirements.
Establishments are not required by law to respond to an FDA 483. However, if an establishment is unable to show that it complies with CGMP requirements to FDA’s satisfaction, FDA may take further enforcement action, including by issuing a warning or untitled letter, seizing product manufactured by the establishment, or seeking an injunction. Responding to the FDA 483 gives establishments an opportunity to explain, among other things, how the establishment has addressed or plans to address the listed observations. The written FDA 483 response will then become a key component of FDA’s review in evaluating whether additional Agency action is warranted.
FDA’s Draft Guidance on Responding to FDA 483s
On March 9, FDA issued a draft guidance for industry providing its recommendations for how establishments can respond to inspectional observations. The draft guidance provides technical and substantive recommendations for a response:
Technical Recommendations for Submission
|
Response Format and Content
|
The response should include the following content in English:
- Table of contents
- Identity of establishment submitting the response, including the establishment’s name, full address of the inspected site, and the inspected site’s FDA Establishment Identifier (FEI)
- Copy of the FDA 483 issued at the close of the inspection
- Identity of the response preparer and, if not prepared by the establishment, the preparer’s relationship to the establishment (e.g. establishment’s consultant, agent, or outside counsel)
- Identity of the signatory of the written response
- FDA recommends that the response be signed by a person in the establishment’s executive management who allocates resources and has the authority to implement commitments.
- Any letters of authorization, if the establishment has retained a consultant or outside counsel
- Any associated global investigation plans and reports, prepared by the establishment or others
- Executive summary of all remediation activities with key details, including a detailed description of each observation or grouped observations and associated remediation activities
- Discussion of each FDA 483 observation and other items as appropriate
|
|
Interim Reporting
|
- For any remediation activities that are not complete, consider submitting preliminary results with a timeline for completion and interim measures added until the CAPA is completed
- Develop a communication plan to FDA for all ongoing remediation activities
|
|
Where to Send Responses
|
- Electronically via email to address listed on FDA 483
|
|
Submission Timeframe
|
- Within 15 business days after the FDA 483 was issued
- In the case of complex observations that are not fully addressed within 15 business days, submit a CAPA plan and proposed time frame for substantive responses within 15 business days
|
Substantive Recommendations for Submissions
|
Understanding and Assessing the Observations
|
- During and immediately after the close of an inspection, an establishment’s management should fully understand all observations and assess any related risks to product quality and patient safety.
- Establishments should take timely and appropriate actions based on this risk assessment.
- Actions may include, but are not limited to, notifying customers, recalling drugs, conducting additional testing, adding lots to stability programs, design improvements (e.g., process, equipment, or facility), amending or supplementing drug application or master files, enhanced complaint monitoring, and labeling revisions.
|
|
Management Responsibility
|
- FDA recommends that the responsible officials are notified of potential inspectional observations during the inspection and that they are notified in writing of reports of inspectional observations issued by FDA.
- FDA expects that an establishment’s management reviews the FDA 483 at the facility level and, if applicable, at the corporate level.
- An establishment’s management should form a multidisciplinary investigation team with clear roles and responsibilities to understand an observation and set the foundation for a robust investigation and provide the leadership needed for the successful functioning of a quality system.
|
|
Develop an Investigation Plan and Conduct an Investigation
|
- FDA recommends establishments prepare an investigation plan and include a detailed protocol and methodology.
- This plan should include a scientifically justified and risk-based scope, including justification for any part of an establishment’s operations that is excluded from the investigation.
- A comprehensive investigation plan addressing FDA 483 observations generally includes identifying any related trends, linking any connected FDA 483 observations, assessing risks, and analyzing root causes.
|
|
Develop and Implement a CAPA Plan
|
- FDA encourages establishments to begin developing a CAPA plan during, or immediately after, the close of an inspection to address issues underlying the observations and correct and prevent the issue(s) from recurring.
- A thorough CAPA plan should address the root cause or causes identified during the investigation and be commensurate with the level of the risks identified through a risk assessment (e.g., consider the potential effect on patient health, safety, and product quality), as well as ensure that operational design, procedures, and systems are adequate and modified as necessary.
- A CAPA plan should include a communication plan with clear steps toward completion, timelines, and deliverables.
|
|
Evaluate CAPA Effectiveness
|
- FDA recommends that establishments use a monitoring system to track overall CAPA effectiveness and periodically evaluate their investigation and CAPA systems to identify the need for changes and improvements.
|
|
Resolving Scientific or Technical Disagreements with FDA 483 Observations
|
- In the event that a significant scientific or technical disagreement is not resolved with the FDA representative(s) before issuance of an FDA 483 that includes the contested observations, establishments should communicate those concerns in the FDA 483 response.
- The response should describe the contested facts and provide scientific data and supporting information to allow FDA to evaluate the issue.
- FDA also recommends that establishments reference any applicable FDA statutes, regulations, or guidance as part of their response.
|
If you have any questions concerning the material discussed in this client alert, please contact members of our Food, Drug, and Device practice. We are available to assist with preparing comments in response to this draft guidance.
Back
